256 related articles for article (PubMed ID: 12370753)
1. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
Farag SS; Archer KJ; Mrózek K; Vardiman JW; Carroll AJ; Pettenati MJ; Moore JO; Kolitz JE; Mayer RJ; Stone RM; Larson RA; Bloomfield CD
Int J Oncol; 2002 Nov; 21(5):1041-51. PubMed ID: 12370753
[TBL] [Abstract][Full Text] [Related]
2. Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT.
Chevallier P; Labopin M; Nagler A; Ljungman P; Verdonck LF; Volin L; Zander AR; Finke J; Socie G; Cordonnier C; Harousseau JL; Mohty M; Rocha V;
Bone Marrow Transplant; 2009 Nov; 44(9):589-94. PubMed ID: 19349953
[TBL] [Abstract][Full Text] [Related]
3. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461.
Byrd JC; Lawrence D; Arthur DC; Pettenati MJ; Tantravahi R; Qumsiyeh M; Stamberg J; Davey FR; Schiffer CA; Bloomfield CD
Clin Cancer Res; 1998 May; 4(5):1235-41. PubMed ID: 9607582
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
5. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
6. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.
Fung HC; Stein A; Slovak Ml; O'donnell MR; Snyder DS; Cohen S; Smith D; Krishnan A; Spielberger R; Bhatia R; Bhatia S; Falk P; Molina A; Nademanee A; Parker P; Rodriguez R; Rosenthal J; Sweetman R; Kogut N; Sahebi F; Popplewell L; Vora N; Somlo G; Margolin K; Chow W; Smith E; Forman SJ
Biol Blood Marrow Transplant; 2003 Dec; 9(12):766-71. PubMed ID: 14677116
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
Koh Y; Kim I; Bae JY; Song EY; Kim HK; Yoon SS; Lee DS; Park SS; Park MH; Park S; Kim BK
Jpn J Clin Oncol; 2010 Nov; 40(11):1037-45. PubMed ID: 20587614
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.
Krauter J; Wagner K; Schäfer I; Marschalek R; Meyer C; Heil G; Schaich M; Ehninger G; Niederwieser D; Krahl R; Büchner T; Sauerland C; Schlegelberger B; Döhner K; Döhner H; Schlenk RF; Ganser A
J Clin Oncol; 2009 Jun; 27(18):3000-6. PubMed ID: 19380453
[TBL] [Abstract][Full Text] [Related]
9. [Studies of treatment strategy and prognosis on acute myeloid leukemia with chromosome 8 and 21 translocation].
Shi HX; Jiang B; Qiu JY; Lu XJ; Fu JF; Wang DB; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):481-4. PubMed ID: 16383240
[TBL] [Abstract][Full Text] [Related]
10. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
11. Trisomy 8 as sole anomaly or with other clonal aberrations in acute myeloid leukemia: impact on clinical presentation and outcome.
Jaff N; Chelghoum Y; Elhamri M; Tigaud I; Michallet M; Thomas X
Leuk Res; 2007 Jan; 31(1):67-73. PubMed ID: 16814381
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
13. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.
Yang DH; Lee JJ; Mun YC; Shin HJ; Kim YK; Cho SH; Chung IJ; Seong CM; Kim HJ
Am J Hematol; 2007 Jan; 82(1):1-5. PubMed ID: 16986129
[TBL] [Abstract][Full Text] [Related]
14. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X;
Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529
[TBL] [Abstract][Full Text] [Related]
15. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
16. Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia.
Jung AS; Holman PR; Castro JE; Carrier EK; Bashey A; Lane TA; Nelson CL; Pu M; Messer K; Corringham SM; Ball ED
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1306-13. PubMed ID: 19747639
[TBL] [Abstract][Full Text] [Related]
17. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
[TBL] [Abstract][Full Text] [Related]
19. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J;
Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
van der Straaten HM; van Biezen A; Brand R; Schattenberg AV; Egeler RM; Barge RM; Cornelissen JJ; Schouten HC; Ossenkoppele GJ; Verdonck LF;
Haematologica; 2005 Oct; 90(10):1339-45. PubMed ID: 16219570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
